| 11.47 -0.11 (-0.95%) | 07-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.58 | 1-year : | 17.03 |
| Resists | First : | 12.48 | Second : | 14.58 |
| Pivot price | 10.66  |
|||
| Supports | First : | 9.51 |
Second : | 7.67 |
| MAs | MA(5) : | 11.3 |
MA(20) : | 10.23 |
| MA(100) : | 6.8 |
MA(250) : | 7.18 |
|
| MACD | MACD : | 1.2 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 74.2 |
D(3) : | 72 |
| RSI | RSI(14): 69.1 |
|||
| 52-week | High : | 13.23 | Low : | 1.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ REPL ] has closed below upper band by 29.8%. Bollinger Bands are 1.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.76 - 11.83 | 11.83 - 11.89 |
| Low: | 11.18 - 11.25 | 11.25 - 11.31 |
| Close: | 11.37 - 11.48 | 11.48 - 11.59 |
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Fri, 03 Jul 2026
REPL Stock On Track For Worst Drop In Nearly 7 Months Ahead Of FDA Decision On Skin Cancer Drug - Stocktwits
Fri, 03 Jul 2026
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
Tue, 30 Jun 2026
Replimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be Crucial (REPL) - Seeking Alpha
Tue, 30 Jun 2026
Replimune (REPL) Receives Double Upgrade Amid Positive FDA Devel - GuruFocus
Mon, 29 Jun 2026
Replimune’s melanoma drug review moves toward Aug. 2 FDA decision - Stock Titan
Sun, 28 Jun 2026
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Shareholde - The National Law Review
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 83 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 96.9 (%) |
| Shares Short | 22,890 (K) |
| Shares Short P.Month | 23,660 (K) |
| EPS | -3.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.64 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.3 % |
| Return on Equity (ttm) | -90.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -278 (M) |
| Levered Free Cash Flow | -173 (M) |
| PE Ratio | -3.34 |
| PEG Ratio | 0 |
| Price to Book value | 4.34 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|